The safety of thoracentesis in patients with uncorrected bleeding risk

Jonathan T. Puchalski*, A. Christine Argento, Terrence E. Murphy, Katy L B Araujo, Margaret A. Pisani

*Corresponding author for this work

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Thoracentesis is commonly performed to evaluate pleural effusions. Many medications (warfarin, heparin, clopidogrel) or physiological factors (elevated International Normalized Ratio [INR], thrombocytopenia, uremia) increase the risk for bleeding. Frequently these medications are withheld or transfusions are performed to normalize physiological parameters before a procedure. The safety of performing thoracentesis without correction of these bleeding risks has not been prospectively evaluated. Methods: This prospective observational cohort study enrolled 312 patients who underwent thoracentesis. All patients were evaluated for the presence of risk factors for bleeding. Hematocrit levels were obtained pre- and postprocedure, and the occurrence of postprocedural hemothorax was evaluated. Measurements and Main Results: Thoracenteses were performed in 312 patients, 42% of whom had a risk for bleeding. Elevated INR, secondary to liver disease or warfarin, and renal disease were the two most common etiologies for bleeding risk, although many patients had multiple potential bleeding risks. There was no significant difference in pre- and postprocedural hematocrit levels in patients with a bleeding risk when compared with patients with no bleeding risk. No patient developed a hemothorax as a result of the thoracentesis. Conclusions: This single-center, observational study suggests that thoracentesis may be safely performed without prior correction of coagulopathy, thrombocytopenia, or medication-induced bleeding risk. This may reduce the morbidity associated with transfusions or withholding of medications.

Original languageEnglish (US)
Pages (from-to)336-341
Number of pages6
JournalAnnals of the American Thoracic Society
Volume10
Issue number4
DOIs
StatePublished - Aug 1 2013

Fingerprint

Hemorrhage
Safety
Hemothorax
International Normalized Ratio
clopidogrel
Warfarin
Hematocrit
Thrombocytopenia
Observational Studies
Thoracentesis
Uremia
Pleural Effusion
Heparin
Liver Diseases
Cohort Studies
Morbidity
Kidney

Keywords

  • Coagulopathy
  • Pleural cavity
  • Pleural effusion
  • Thoracentesis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Puchalski, Jonathan T. ; Argento, A. Christine ; Murphy, Terrence E. ; Araujo, Katy L B ; Pisani, Margaret A. / The safety of thoracentesis in patients with uncorrected bleeding risk. In: Annals of the American Thoracic Society. 2013 ; Vol. 10, No. 4. pp. 336-341.
@article{460f6da7918d445da4fb934f23900f97,
title = "The safety of thoracentesis in patients with uncorrected bleeding risk",
abstract = "Background: Thoracentesis is commonly performed to evaluate pleural effusions. Many medications (warfarin, heparin, clopidogrel) or physiological factors (elevated International Normalized Ratio [INR], thrombocytopenia, uremia) increase the risk for bleeding. Frequently these medications are withheld or transfusions are performed to normalize physiological parameters before a procedure. The safety of performing thoracentesis without correction of these bleeding risks has not been prospectively evaluated. Methods: This prospective observational cohort study enrolled 312 patients who underwent thoracentesis. All patients were evaluated for the presence of risk factors for bleeding. Hematocrit levels were obtained pre- and postprocedure, and the occurrence of postprocedural hemothorax was evaluated. Measurements and Main Results: Thoracenteses were performed in 312 patients, 42{\%} of whom had a risk for bleeding. Elevated INR, secondary to liver disease or warfarin, and renal disease were the two most common etiologies for bleeding risk, although many patients had multiple potential bleeding risks. There was no significant difference in pre- and postprocedural hematocrit levels in patients with a bleeding risk when compared with patients with no bleeding risk. No patient developed a hemothorax as a result of the thoracentesis. Conclusions: This single-center, observational study suggests that thoracentesis may be safely performed without prior correction of coagulopathy, thrombocytopenia, or medication-induced bleeding risk. This may reduce the morbidity associated with transfusions or withholding of medications.",
keywords = "Coagulopathy, Pleural cavity, Pleural effusion, Thoracentesis",
author = "Puchalski, {Jonathan T.} and Argento, {A. Christine} and Murphy, {Terrence E.} and Araujo, {Katy L B} and Pisani, {Margaret A.}",
year = "2013",
month = "8",
day = "1",
doi = "10.1513/AnnalsATS.201210-088OC",
language = "English (US)",
volume = "10",
pages = "336--341",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "4",

}

The safety of thoracentesis in patients with uncorrected bleeding risk. / Puchalski, Jonathan T.; Argento, A. Christine; Murphy, Terrence E.; Araujo, Katy L B; Pisani, Margaret A.

In: Annals of the American Thoracic Society, Vol. 10, No. 4, 01.08.2013, p. 336-341.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The safety of thoracentesis in patients with uncorrected bleeding risk

AU - Puchalski, Jonathan T.

AU - Argento, A. Christine

AU - Murphy, Terrence E.

AU - Araujo, Katy L B

AU - Pisani, Margaret A.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Background: Thoracentesis is commonly performed to evaluate pleural effusions. Many medications (warfarin, heparin, clopidogrel) or physiological factors (elevated International Normalized Ratio [INR], thrombocytopenia, uremia) increase the risk for bleeding. Frequently these medications are withheld or transfusions are performed to normalize physiological parameters before a procedure. The safety of performing thoracentesis without correction of these bleeding risks has not been prospectively evaluated. Methods: This prospective observational cohort study enrolled 312 patients who underwent thoracentesis. All patients were evaluated for the presence of risk factors for bleeding. Hematocrit levels were obtained pre- and postprocedure, and the occurrence of postprocedural hemothorax was evaluated. Measurements and Main Results: Thoracenteses were performed in 312 patients, 42% of whom had a risk for bleeding. Elevated INR, secondary to liver disease or warfarin, and renal disease were the two most common etiologies for bleeding risk, although many patients had multiple potential bleeding risks. There was no significant difference in pre- and postprocedural hematocrit levels in patients with a bleeding risk when compared with patients with no bleeding risk. No patient developed a hemothorax as a result of the thoracentesis. Conclusions: This single-center, observational study suggests that thoracentesis may be safely performed without prior correction of coagulopathy, thrombocytopenia, or medication-induced bleeding risk. This may reduce the morbidity associated with transfusions or withholding of medications.

AB - Background: Thoracentesis is commonly performed to evaluate pleural effusions. Many medications (warfarin, heparin, clopidogrel) or physiological factors (elevated International Normalized Ratio [INR], thrombocytopenia, uremia) increase the risk for bleeding. Frequently these medications are withheld or transfusions are performed to normalize physiological parameters before a procedure. The safety of performing thoracentesis without correction of these bleeding risks has not been prospectively evaluated. Methods: This prospective observational cohort study enrolled 312 patients who underwent thoracentesis. All patients were evaluated for the presence of risk factors for bleeding. Hematocrit levels were obtained pre- and postprocedure, and the occurrence of postprocedural hemothorax was evaluated. Measurements and Main Results: Thoracenteses were performed in 312 patients, 42% of whom had a risk for bleeding. Elevated INR, secondary to liver disease or warfarin, and renal disease were the two most common etiologies for bleeding risk, although many patients had multiple potential bleeding risks. There was no significant difference in pre- and postprocedural hematocrit levels in patients with a bleeding risk when compared with patients with no bleeding risk. No patient developed a hemothorax as a result of the thoracentesis. Conclusions: This single-center, observational study suggests that thoracentesis may be safely performed without prior correction of coagulopathy, thrombocytopenia, or medication-induced bleeding risk. This may reduce the morbidity associated with transfusions or withholding of medications.

KW - Coagulopathy

KW - Pleural cavity

KW - Pleural effusion

KW - Thoracentesis

UR - http://www.scopus.com/inward/record.url?scp=84883371626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883371626&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201210-088OC

DO - 10.1513/AnnalsATS.201210-088OC

M3 - Article

VL - 10

SP - 336

EP - 341

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 4

ER -